Lipocine (LPCN) Projected to Release Earnings on Tuesday

Lipocine (NASDAQ:LPCN – Get Free Report) is expected to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Lipocine to announce earnings of ($0.40) per share and revenue of $0.2130 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

Lipocine (NASDAQ:LPCN – Get Free Report) last posted its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The company had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.16 million. Lipocine had a negative net margin of 571.18% and a negative return on equity of 66.70%.

Get Lipocine alerts:

Lipocine Trading Up 2.6%

Shares of NASDAQ:LPCN opened at $2.19 on Tuesday. The stock has a market cap of $18.09 million, a P/E ratio of -1.17 and a beta of 0.44. The company has a 50 day moving average of $2.29 and a 200 day moving average of $5.10. Lipocine has a 12 month low of $1.81 and a 12 month high of $12.37.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LPCN. Squadron Capital Management LLC bought a new stake in Lipocine during the 4th quarter valued at about $4,256,000. Diadema Partners LP bought a new position in shares of Lipocine during the 4th quarter valued at $2,095,000. Ikarian Capital LLC bought a new position in Lipocine in the fourth quarter valued at about $1,602,000. Boothbay Fund Management LLC bought a new position in shares of Lipocine in the 4th quarter worth approximately $441,000. Finally, Citadel Advisors LLC bought a new position in Lipocine in the third quarter worth approximately $41,000. Institutional investors own 9.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on LPCN. Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a research note on Saturday, July 18th. Weiss Ratings lowered Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. Finally, HC Wainwright reissued a “neutral” rating on shares of Lipocine in a research report on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $15.00.

Get Our Latest Stock Report on LPCN

About Lipocine

(Get Free Report)

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.

Read More

• Five stocks we like better than Lipocine
• 3 Stocks Standing Out and 2 Losing Momentum as the Tech Rally Cracks
• 5 AI Stocks Are Pulling Back—Which Growth Catalysts Still Look Strongest?
• Middleby Is Betting a Leaner Business Can Unlock More Value
• 3 Value ETFs to Consider as Growth Stocks Lag Behind

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.